Biotechnology

Adicet Bio, Inc. announced an inducement award to a new employee joining in September 2025. The individual received a non-qualified stock option to purchase 9,800 shares at $0.81 per share, the closing price on the grant date. The options vest over four years with a one-year cliff, contingent upon continued employment. The award was granted under the 2022 Inducement Plan and approved by the independent compensation committee, adhering to Nasdaq Listing Rule 5635(c)(4). Adicet Bio focuses on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

Defence Therapeutics (DTCFF) appointed Dr. Amie Phinney to its Board of Directors. Dr. Phinney, previously a Strategy and Business Advisor, will now contribute to corporate governance and value creation as the company advances its drug-delivery platform. Defence granted her 100,000 stock options, exercisable at $0.75 per share. This appointment aims to enhance the company’s leadership and capitalize on Dr. Phinney’s pharma and biotech expertise, potentially impacting treatment landscapes.

Revive Therapeutics (RVVTF) is extending its private placement to raise up to $650,000 by issuing units at $0.021 each. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. Having already raised $60,900 in the first tranche, the remaining $589,000 will be used for working capital and settling trade payables. The securities are subject to a four-month and one-day hold period. While providing needed capital, the offering involves significant dilution potential for shareholders.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.

Innate Pharma announced its total outstanding shares and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and 6,434, plus 7,581 preferred shares. Total theoretical voting rights stood at 92,962,943, with 92,944,368 exercisable rights. This disclosure complies with French regulatory requirements.

SOHM, Inc. appointed Ravi Kapoor as an Independent Director. Kapoor brings over 30 years of experience in corporate law, M&A, and financial management. His expertise is expected to enhance SOHM’s strategic direction, corporate governance, and growth initiatives, particularly aligning with the company’s focus on generic drugs and gene-editing technologies.

Lipella Pharmaceuticals Inc. is delisted from the Nasdaq Capital Market due to rule violations regarding private placement transactions. The delisting, involving the issuance of convertible preferred stock and warrants, led to the suspension of trading. While disappointed, the company is exploring alternative markets, remains focused on its clinical development plans for LP-10 and LP-310, and is pressing forward with its mission to address unmet medical needs.

GRI Bio (NASDAQ: GRI), a San Diego-based biotech targeting iNKT cells for autoimmune therapies, will present its immunomodulatory platform at A.G.P.’s 2025 Healthcare Showcase on May 21 (2:40 PM ET) via live webcast. Dr. Marc Hertz, CEO, will outline advancements over traditional CAR-T approaches and highlight upcoming Phase II results for GRI-0621 (IPF/lupus pipelines) and its 500-compound library. The event attracts 500+ investors and historically correlates with 8% stock performance gains, offering critical visibility for the company’s early-inflammation intervention strategy. [99 words]

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company developing Treg-targeted therapies for neuroinflammatory diseases, will headline H.C. Wainwright’s BioConnect Conference in New York City on May 16, 2025. CEO Dr. Arun Swaminathan will discuss the integration of its proprietary platforms, including lead compound COYA 302—a dual-pathway subcutaneous treatment combining LD IL-2 and CTLA4-Ig to address neuroinflammation. The company emphasizes its platforms’ potential in neurodegenerative, autoimmune, and metabolic disorders, while noting risks related to clinical timelines, regulation, and capital intensity in SEC filings. A live stream of the conference session will be available on its investor relations page for 90 days.